ECM
BPMC

Everence Capital Management’s Blueprint Medicines BPMC Stock Holding History

Everence Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,090
Closed -$268K – 807
2025
Q2 		$268K Buy
+2,090
New +$217K 0.02% 625

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Everence Capital Management's BPMC Position: Q3 2025 in Review

Everence Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,090 shares — an estimated $268K sold.

Everence Capital Management first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $268K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Everence Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Everence Capital Management sold 2,090 Blueprint Medicines shares in Q3 2025, an estimated $268K.
  • Everence Capital Management first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Everence Capital Management's Blueprint Medicines position peaked at $268K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Everence Capital Management's 13F filing for Q3 2025, filed 1 Oct 2025.